OGA mutant aberrantly hydrolyzes O-GlcNAc modification from PDLIM7 to modulate p53 and cytoskeleton in promoting cancer cell malignancy
Proceedings of the National Academy of Sciences · 2024
DOI: 10.1073/pnas.2320867121 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2024. Verfasst von Chia-Wei Hu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical Sciences Division, School of Pharmacy, University of Wisconsin-Madison, Madison, WI 53705. Hauptthemen laut MEDLINE: Tumor Suppressor Protein p53, LIM Domain Proteins, Cytoskeleton. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIGMS NIH HHS, NIH HHS, NIA NIH HHS.
Abstract (Originalsprache)
O-GlcNAcase (OGA) is the only human enzyme that catalyzes the hydrolysis (deglycosylation) of O-linked beta- N -acetylglucosaminylation (O-GlcNAcylation) from numerous protein substrates. OGA has broad implications in many challenging diseases including cancer. However, its role in cell malignancy remains mostly unclear. Here, we report that a cancer-derived point mutation on the OGA’s noncatalytic stalk domain aberrantly modulates OGA interactome and substrate deglycosylation toward a specific set of proteins. Interestingly, our quantitative proteomic studies uncovered that the OGA stalk domain mutant preferentially deglycosylated protein substrates with +2 proline in the sequence relative to the O-GlcNAcylation site. One of the most dysregulated substrates is PDZ and LIM domain protein 7 (PDLIM7), which is associated with the tumor suppressor p53. We found that the aberrantly deglycosylated PDLIM7 suppressed p53 gene expression and accelerated p53 protein degradation by promoting the complex formation with E3 ubiquitin ligase MDM2. Moreover, deglycosylated PDLIM7 significantly up-regulated the actin-rich membrane protrusions on the cell surface, augmenting the cancer cell motility and aggressiveness. These findings revealed an important but previously unappreciated role of OGA’s stalk domain in protein substrate recognition and functional modulation during malignant cell progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pharmaceutical Sciences Division, School of Pharmacy, University of Wisconsin-Madison, Madison, WI 53705.
- Department of Chemistry, University of Wisconsin-Madison, Madison, WI 53706.
ORCID-Profile: Ao Wang, Jinshan Xie, Lingjun Li, Jiaoyang Jiang
Förderung
- NIGMS NIH HHS
- NIH HHS
- NIA NIH HHS
- HHS | NIH | National Institute on Aging (NIA)
- NIDDK NIH HHS
- NCRR NIH HHS
- HHS | NIH | National Institute of General Medical Sciences (NIGMS)
- HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases
Zitieren
APA
Hu, C. W., Wang, A., Fan, D., Worth, M., Chen, Z., Huang, J., Xie, J., Macdonald, J., Li, L., & Jiang, J. (2024). OGA mutant aberrantly hydrolyzes O-GlcNAc modification from PDLIM7 to modulate p53 and cytoskeleton in promoting cancer cell malignancy. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2320867121
Vancouver
Hu CW, Wang A, Fan D, Worth M, Chen Z, Huang J, et al. OGA mutant aberrantly hydrolyzes O-GlcNAc modification from PDLIM7 to modulate p53 and cytoskeleton in promoting cancer cell malignancy. Proceedings of the National Academy of Sciences. 2024. doi:10.1073/pnas.2320867121
BibTeX
@article{Hu2024,
author = {Hu, Chia-Wei and Wang, Ao and Fan, Dacheng and Worth, Matthew and Chen, Zhengwei and Huang, Junfeng and Xie, Jinshan and Macdonald, John and Li, Lingjun and Jiang, Jiaoyang},
title = {OGA mutant aberrantly hydrolyzes O-GlcNAc modification from PDLIM7 to modulate p53 and cytoskeleton in promoting cancer cell malignancy},
journal = {Proceedings of the National Academy of Sciences},
year = {2024},
doi = {10.1073/pnas.2320867121}
}
EUVIMED